nach oben

Journal of Neurology

Erschienen in:

03.09.2018 | Original Communication

Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy

verfasst von: Gabriella Santangelo, Sofia Cuoco, Maria Teresa Pellecchia, Roberto Erro, Paolo Barone, Marina Picillo

Erschienen in: Journal of Neurology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Parkinsonian syndromes are characterized by a wide spectrum of non-motor symptoms. A few studies explored cognitive deficits and neuropsychiatric symptoms in atypical parkinsonism compared to Parkinson’s disease (PD). The study was performed to identify cognitive and neuropsychiatric differences between PD, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) and to evaluate the influence of clinical features, depressive symptomatology and apathy on cognitive performances in the three groups.

Methods

Fifty-five PD, 44 MSA and 42 PSP patients underwent cognitive tests assessing attention, language, memory, visuospatial and executive functions as well as scales assessing depression and apathy. Out of these patients, 20 PD, 20 MSA and 20 PSP patients were selected to be matched for age, education and global cognitive status. Within each whole patients group, correlational analysis was performed between clinical, behavioural and cognitive parameters.

Results

The main difference among the groups matched was on cognitive tests exploring verbal learning, executive and linguistic functions. The PSP group was more impaired than the PD and MSA groups on cognitive tests assessing executive functions. On the other hand, MSA group obtained similar cognitive performance to the PD group. As to behavioural symptoms, in whole PSP and MSA groups, apathy and depression were more severe than in PD group, while apathy (but not depression) were more severe in the PSP group as compared to the MSA group.

Conclusions

The present study underlined the pervasiveness of cognitive deficits, apathy and depressive symptoms in PSP, whereas little cognitive differences were found between PD and MSA. The findings indirectly supported a dysfunction of prefronto-subcortical circuitries (i.e., dorsolateral prefrontal and limbic circuits) in PSP and PD. Cognitive similarities between MSA and PD reinforced the pivotal role of altered basal ganglia and corresponding frontal deafferentation in the occurrence of the cognitive deficits.

Nur mit Berechtigung zugänglich

Gerstenecker A (2017) The neuropsychology (broadly conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Arch Clin Neuropsychol 32(7):861–875CrossRef

Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9(12):1200–1213CrossRef

Bak TH, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR (2005) Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 11(4):268–273CrossRef

Brown RG, Lacomblez L, Landwehrmeyer BG et al (2010) Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 133(Pt 8):2382–2393CrossRef

Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD (1997) Apraxia in Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 120(Pt 1):75–90CrossRef

Pillon B, Gouider-Khouja N, Deweer B et al (1995) Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 58(2):174–179CrossRef

Krishnan S, Mathuranath PS, Sarma S, Kishore A (2006) Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson’s disease. Neurol India 54(3):268–272CrossRef

Lange KW, Tucha O, Alders GL et al (2003) Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm (Vienna) 110(9):983–995CrossRef

Monza D, Soliveri P, Radice D et al (1998) Cognitive dysfunction and impaired organization of complex motility in degenerative parkinsonian syndromes. Arch Neurol 55(3):372–378CrossRef

10.

Robbins TW, James M, Owen AM et al (1994) Cognitive deficits in progressive supranuclear palsy, Parkinson’s disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 57(1):79–88CrossRef

11.

Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13(1):42–49CrossRef

12.

Schrag A, Sheikh S, Quinn NP et al (2010) A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 25(8):1077–1081CrossRef

13.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRef

14.

Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–676CrossRef

15.

Litvan I, Agid Y, Jankovic J et al (1996) Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome). Neurology 46(4):922–930CrossRef

16.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRef

17.

Katz TF (1963) A.D.L. activities of daily living. JAMA 185:914CrossRef

18.

Lawton MP, Brody EM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186CrossRef

19.

Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent developments in Parkinson’s disease. MacMillan, Florham Park, pp 153–304

20.

Wenning GK, Tison F, Seppi K et al (2004) Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 19(12):1391–1402CrossRef

21.

Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt 6):1552–1565CrossRef

22.

Santangelo G, Siciliano M, Pedone R et al (2015) Normative data for the Montreal Cognitive Assessment in an Italian population sample. Neurol Sci 36(4):585–591CrossRef

23.

Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 17(4):305–309CrossRef

24.

Caltagirone C, Gainotti G, Masullo C, Miceli G (1979) Validity of some neuropsychological test in the assessment of mental deterioration. Acta Psychiatr Scand 60:50–56CrossRef

25.

Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E (1998) A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 19(3):161–170CrossRef

26.

Siciliano M, Santangelo G, D’Iorio A et al (2016) Rouleau version of the Clock Drawing Test: age- and education-adjusted normative data from a wide Italian sample. Clin Neuropsychol 30(sup1):1501–1516CrossRef

27.

Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Rey–Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 22(6):443–447CrossRef

28.

Novelli G, Papagno C, Capitani E, Laiacona M, Vallar G, Cappa SF (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Arch Psicol Neurol Psichiatria 47(4):477–506

29.

Capasso R, Miceli G (2001) Esame Neuropsicologico per l’Afasia, ENPA. Springer, Milan

30.

Ferracuti S, Sacco R, Cannoni E, Hufty AM, Silvan AB, Hamster KDeS, Varney NR, Spreen O (2000) Contributi per un Assessment Neuropsicologico di Benton AL. Organizzazioni Speciali, Florence

31.

Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di una batteria di test neuropsicologici. Ital J Neurol Sci 8:1–120

32.

Ghisi M, Flebus GB, Montano A, Sanavio E, Sica C (2006) Beck Depression Inventory-Second Edition. Adattamento italiano: Manuale. Organizzazioni Speciali, Florence

33.

Santangelo G, Barone P, Cuoco S et al (2014) Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale. J Neurol 261(12):2319–2328CrossRef

34.

Pitman EJG (1948) Lecture notes on nonparametric statistical inference: lectures given for the University of North Carolina. Columbia University, New York

35.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552–563CrossRef

36.

Stankovic I, Krismer F, Jesic A et al (2014) Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 29(7):857–867CrossRef

37.

Houghton DJ, Litvan I (2007) Unraveling progressive supranuclear palsy: from the bedside back to the bench. Parkinson Relat Disord Suppl 3:S341–S346CrossRef

38.

Rosskopf J, Gorges M, Müller HP et al (2017) Intrinsic functional connectivity alterations in progressive supranuclear palsy: differential effects in frontal cortex, motor, and midbrain networks. Mov Disord 32(7):1006–1015CrossRef

39.

Messina D, Cerasa A, Condino F et al (2011) Patterns of brain atrophy in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. Parkinson Relat Disord 17(3):172–176CrossRef

40.

Schulz JB, Skalej M, Wedekind D et al (1999) Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson’s syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 45(1):65–74CrossRef

41.

Rusz J, Bonnet C, Klempíř J et al (2015) Speech disorders reflect differing pathophysiology in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. J Neurol 262(4):992–1001CrossRef

42.

Daniele A, Barbier A, Di Giuda D et al (2013) Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy. Cortex 49(4):948–960CrossRef

43.

Rodríguez-Ferreiro J, Menéndez M, Ribacoba R, Cuetos F (2009) Action naming is impaired in Parkinson disease patients. Neuropsychologia 47(14):3271–3274CrossRef

44.

Silveri MC, Ciccarelli N, Baldonero E, Piano C, Zinno M, Soleti F, Bentivoglio AR, Albanese A, Daniele A (2012) Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson’s disease. Neuropsychologia 50(8):1980–1989CrossRef

45.

Litvan I, Mega MS, Cummings JL, Fairbanks L (1996) Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 47(5):1184–1189CrossRef

46.

Santangelo G, Vitale C, Trojano L et al (2015) Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson’s disease: a prospective longitudinal study. Eur J Neurol 22(2):253–260CrossRef

47.

Santangelo G, D’Iorio A, Maggi G et al (2018) Cognitive correlates of “pure apathy” in Parkinson’s disease. Parkinson Relat Disord. https://doi.org/10.1016/j.parkreldis.2018.04.023 CrossRef

48.

D’Iorio A, Maggi G, Vitale C, Trojano L, Santangelo G (2018) “Pure apathy” and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study. Neurosci Biobehav Rev 94:1–10. https://doi.org/10.1016/j.neubiorev.2018.08.004 CrossRefPubMed

49.

Santangelo G, Vitale C, Picillo M et al (2015) Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinson Relat Disord 21(5):489–493CrossRef

50.

Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I (1998) Apathy is not depression. J Neuropsychiatry Clin Neurosci 10(3):314–319CrossRef

51.

Cordato NJ, Halliday GM, Caine D et al (2006) Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 21:632–638CrossRef

52.

Lee CN, Kim M, Lee HM, Jang JW, Lee SM, Kwon DY, Park KW, Koh SB (2013) The interrelationship between non-motor symptoms in Atypical Parkinsonism. J Neurol Sci 327(1–2):15–21CrossRef

53.

Cordato NJ, Pantelis C, Halliday GM et al (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125:789–800CrossRef

54.

Wenning GK, Ben-Shlomo BY, Megalhães M et al (1994) Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 117:835–845CrossRef

55.

Tison F, Yekhlef F, Chrysostome V (2006) Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson’s disease. Mov Disord 21(7):1056–1057CrossRef

56.

Duff K, Gerstenecker A, Litvan I, Investigators and Coordinators of the ENGENE-PSP Study Group (2013) Functional impairment in progressive supranuclear palsy. Neurology 80(4):380–384CrossRef

57.

Diamond A (2013) Executive functions. Annu Rev Psychol 64:135–168CrossRef

58.

Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853–864CrossRef

Titel: Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy
verfasst von: Gabriella Santangelo
Sofia Cuoco
Maria Teresa Pellecchia
Roberto Erro
Paolo Barone
Marina Picillo
Publikationsdatum: 03.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 11/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9038-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy

Abstract

Background

Methods

Results

Conclusions

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Targeting phosphocreatine metabolism in relapsing–remitting multiple sclerosis: evaluation with brain MRI, 1H and 31P MRS, and clinical and cognitive testing

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes

Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers

The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study

Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients

Quality of life in a German cohort of Parkinson’s patients assessed with three different measures

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie